Alnylam Pharmaceuticals reported that its RNAi therapeutic zilebesiran failed to significantly reduce blood pressure in a pivotal Phase 2 study, casting uncertainty on the drug’s benefit as it moves into late-stage trials. Despite weak blood pressure reductions that were not statistically significant, Alnylam plans to initiate a Phase 3 cardiovascular outcomes trial this year. The data were presented at the European Society of Cardiology meeting.